3-Step Evaluation for Optimal Aromatase Inhibitor Selection

1. Compare Key Side Effect Differences

  1. Anastrozole (Arimidex): Generally causes fewer joint pains than letrozole but may increase cholesterol
  2. Letrozole (Femara): Higher efficacy in some studies but greater incidence of musculoskeletal symptoms
  3. Exemestane (Aromasin): Steroidal structure may benefit patients experiencing tendon issues with other AIs
Clinical data shows 58% patients report side effects with letrozole vs 49% with anastrozole (JCO 2021 meta-analysis)

2. Match Drug Profile to Your Health History

  1. For osteoporosis risk: Exemestane's androgenic properties may offer slight bone protection
  2. With pre-existing joint issues: Anastrozole often better tolerated initially
  3. For maximum efficacy: Letrozole demonstrates marginally better survival rates in certain subgroups

3. Implement Side Effect Mitigation Strategies

  1. Joint pain: Vitamin D + omega-3 supplementation reduces symptoms in 68% cases
  2. Hot flashes: Low-dose venlafaxine decreases frequency by 50% in clinical trials
  3. Bone health: Biannual DEXA scans + weight-bearing exercise protocol